The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

A key European regulatory panel has reversed course and is now recommending approval of Leqembi, the Alzheimer's drug from Biogen and Eisai. The companies on Thursday said the European Medicines ...

An Italian Dance has managed to raise £3000 for the charity Alzheimer’s Society. The event that happened on Saturday at Arnos Manor Hotel, is a traditional dance that has not been held locally in more ...

The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

A recent study found that relatively healthy obesity may reduce the risk of developing Alzheimer's disease.

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with ...

She loved gardening and spending time with her daughters, granddaughter and great-granddaughters. The family requests that ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...